Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Clinical and Translational Science
|
July 13, 2026
Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria
Yan Ji, Claudio Calonder, Tiina Kirsiläe, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 23, 2025
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria
Andrzej Bienczak, Aurelie Gautier, Eva Hua, et al.
British Journal of Clinical Pharmacology
|
October 29, 2019
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
Gerard Bruin, Hans-Ulrich P Hockey, Phillip La Stella, et al.
Paediatric Drugs
|
June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Nina Magnolo, Külli Kingo, Vivian Laquer, et al.
Pharmaceutics
|
September 28, 2023
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System
Yan Ji, Claudio Calonder, Tiina Kirsilä, et al.
Journal of the American Academy of Dermatology
|
September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
Nina Magnolo, Külli Kingo, Vivian Laquer, et al.
The Journal of Dermatological Treatment
|
April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
Bardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
The British Journal of Dermatology
|
January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial
Matthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Dermatology and Therapy
|
October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Jerry Bagel, John Nia, Peter W Hashim, et al.
Modern Rheumatology
|
March 24, 2026
Efficacy and safety of canakinumab in patients with Adult-Onset Still's Disease: Results from an open-label Phase III study in Japan
Tatsuya Atsumi, Yohei Kirino, Mitsumasa Kishimoto, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Clinical and Translational Science
|
July 13, 2026
Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria
Yan Ji, Claudio Calonder, Tiina Kirsiläe, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 23, 2025
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria
Andrzej Bienczak, Aurelie Gautier, Eva Hua, et al.
British Journal of Clinical Pharmacology
|
October 29, 2019
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
Gerard Bruin, Hans-Ulrich P Hockey, Phillip La Stella, et al.
Paediatric Drugs
|
June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Nina Magnolo, Külli Kingo, Vivian Laquer, et al.
Pharmaceutics
|
September 28, 2023
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System
Yan Ji, Claudio Calonder, Tiina Kirsilä, et al.
Journal of the American Academy of Dermatology
|
September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
Nina Magnolo, Külli Kingo, Vivian Laquer, et al.
The Journal of Dermatological Treatment
|
April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
Bardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
The British Journal of Dermatology
|
January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial
Matthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Dermatology and Therapy
|
October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Jerry Bagel, John Nia, Peter W Hashim, et al.
Modern Rheumatology
|
March 24, 2026
Efficacy and safety of canakinumab in patients with Adult-Onset Still's Disease: Results from an open-label Phase III study in Japan
Tatsuya Atsumi, Yohei Kirino, Mitsumasa Kishimoto, et al.
Page
of 2